Sunrise Oncology (Hong Kong) Ltd. has synthesized new condensed macrocyclic compounds acting as GTPase KRAS inhibitors potentially useful for the treatment of cancer.
Insmed Inc. has identified new cathepsin C (dipeptidyl peptidase I; DPP1) inhibitors potentially useful for the treatment of cancer, inflammatory bowel disease, bronchiectasis, asthma, cystic fibrosis, lupus nephritis, pulmonary hypertension and rheumatoid arthritis.
HK Inno.N Corp. has disclosed new 5-cyclopropylpicolinamide derivatives acting as mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors potentially useful for the treatment of cancer.
Simcere Zaiming Pharmaceutical Co. Ltd. has detailed the discovery and preclinical characterization of ZMS-2195, a multiple-RAS inhibitor designed to prevent both mutant and wild-type forms of KRAS, NRAS and HRAS from binding to the RAS-binding domain (RBD) of RAF, which is required to activate downstream MAPK signaling.
Biosion Inc. recently presented preclinical data describing their B7H3/PD-L1 bispecific antibody-drug conjugate (ADC) BSI-737 for the treatment of cancer.
CRAC channels are essential for immune and developmental processes, and dysregulation of store-operated Ca2+ entry (SOCE) has been implicated in several human diseases. Researchers from Texas A&M University and collaborators recently described the engineering of genetically encoded CRAC channel inhibitory binders (CRABs) derived from the ORAI C-terminal region, a defined STIM1-binding interface.
Beijing Innocare Pharma Tech Co. Ltd. has received IND approval from China’s National Medical Products Administration (NMPA) for ICP-B208, an antibody-drug conjugate targeting CDH17, which is highly expressed in gastrointestinal cancers, including colorectal, gastric and biliary tract cancers and pancreatic ductal adenocarcinoma.
RSS
